NCT07452562 (NECTAR-MS) is a NA clinical trial of Hesperidin in Multiple Sclerosis, sponsored by Swansea University.

Who is sponsoring NCT07452562?

NCT07452562 is sponsored by Swansea University.

What drugs are being tested in NCT07452562?

Interventions in NCT07452562: Hesperidin, Placebo.

What condition does NCT07452562 study?

NCT07452562 studies Multiple Sclerosis.

Is NCT07452562 still recruiting?

NCT07452562 is currently recruiting now. Last updated 5 March 2026.

Last reviewed 2026-03-05 · How we verify

NCT07452562: NECTAR-MS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Hesperidin RCT in MS

Recruiting now NA Last updated 5 March 2026

What this trial tests

NA trial testing Hesperidin in Multiple Sclerosis in 60 participants. Currently enrolling.

Timeline

7 January 2026

Primary endpoint
18 January 2027

18 January 2027

Quick facts

Lead sponsor	Swansea University
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	60
Start date	7 January 2026
Primary completion	18 January 2027
Estimated completion	18 January 2027
Sites	1 location across United Kingdom

Drugs / interventions tested

Hesperidin — full drug profile →
Placebo

Conditions studied

Multiple Sclerosis — all drugs for Multiple Sclerosis →

Sponsor

Swansea University

Who can join

18 and older, any sex, with Multiple Sclerosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a randomised, double-blind, placebo-controlled trial investigating the effects of Hesperidin supplementation on cognitive function, fatigue, and stress. Participants will be randomly assigned to receive either 500mg of Hesperidin or a matching placebo daily for 12 weeks. The primary outcome is fatigue, with secondary outcomes including cognitive performance and mood. The trial seeks to determine if this dietary intervention offers symptom-alleviating benefits.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Hesperidin

Trials testing the same drug.

NCT06402032 — Clinical and Histological Evaluation of Hesperidin as a Direct Pulp Capping Material · NA · completed
NCT04316390 — Influence of Hesperidin and Vitamin C on Uric Acid Concentration · NA · completed
NCT04715932 — Study of Hesperidin Therapy on COVID-19 Symptoms (HESPERIDIN) · Phase 2 · completed
NCT03377140 — The Effects of Hesperidin on Biochemical Factors and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease · NA · unknown

Other recruiting trials for Multiple Sclerosis

Currently open trials in the same condition.

NCT07507084 — The Effect of Internal- or External-Focused Exercise Training, Administered in Conjunction With a Cognitive Task, on Wal · NA · recruiting
NCT07524231 — Evaluation of the Effects of Laughter Yoga · NA · recruiting
NCT07489794 — URINARY INCONTINENCE AND PELVIC FLOOR MUSCLE ACTIVITY IN MULTIPLE SCLEROSIS · recruiting
NCT07236684 — Identification of Factors Related to UI in Patients With MS and EMG Assessment of PFM Activity · recruiting
NCT07500727 — Skeletal Muscle Aging and Responsiveness in Aged People With MS · NA · recruiting

Other Swansea University trials

Trials by the same sponsor.

NCT07272096 — ACTing Minds: An ACT-based Videogame for Mental Health · NA · completed
NCT06961513 — Patient Evaluation of Treatment of Pelvic-floor Muscle Dysfunction. · not yet recruiting
NCT06698588 — Symptom-specific Effects of Omega-3 Across Neurodevelopmental Symptoms · NA · recruiting
NCT06407557 — Optimizing Older Adults' Home Space for Physical Activity · NA · completed
NCT05591573 — The Impact of Glycemic Index on Sleep and Memory Consolidation · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07452562 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Swansea University
Last refreshed: 5 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07452562.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing